Cyclophosphamide oral 25 mg
Products billed under this code include Cyclophosphamide.
Payment limit per 25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cyclophosphamide.
Payment limit per 25 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cyclophosphamide | Hikma Pharmaceuticals USA Inc. | 00054-0382-25 | 100 | $123.30 |
| Cyclophosphamide | Hikma Pharmaceuticals USA Inc. | 00054-0383-25 | 200 | $246.60 |
| Cyclophosphamide | Baxter Healthcare Corporation | 10019-0984-01 | 200 | $246.60 |
| Cyclophosphamide | Cipla USA, Inc. | 69097-0516-07 | 100 | $123.30 |
| Cyclophosphamide | Cipla USA, Inc. | 69097-0517-07 | 200 | $246.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.233 | −$0.258 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted September 17, 2026 |
| 3Q26 | $1.491 | −$0.158 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted September 15, 2026 |
| 2Q26 | $1.649 | −$0.17 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted September 15, 2026 |
| 1Q26 | $1.819 | +$0.722 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted September 15, 2026 |
| 4Q25 | $1.097 | −$0.885 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted September 8, 2026 |
| 3Q25 | $1.982 | +$0.843 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted March 10, 2026 |
| 2Q25 | $1.139 | +$0.303 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted March 10, 2026 |
| 1Q25 | $0.836 | −$0.047 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted December 19, 2025 |
| 4Q24 | $0.883 | −$0.079 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 11, 2025 |
| 3Q24 | $0.962 | +$0.103 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 11, 2025 |
| 2Q24 | $0.859 | +$0.241 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted March 11, 2025 |
| 1Q24 | $0.618 | −$0.388 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted December 19, 2024 |
| 4Q23 | $1.006 | +$0.053 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted October 10, 2024 |
| 3Q23 | $0.953 | +$0.058 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 5, 2024 |
| 2Q23 | $0.895 | +$0.222 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted February 23, 2024 |
| 1Q23 | $0.673 | +$0.091 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted December 6, 2023 |
| 4Q22 | $0.582 | −$0.173 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 22, 2023 |
| 3Q22 | $0.755 | −$0.223 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 9, 2023 |
| 2Q22 | $0.978 | +$0.094 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted December 14, 2022 |
| 1Q22 | $0.884 | +$0.078 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 8, 2022 |
| 4Q21 | $0.806 | −$0.337 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 2, 2022 |
| 3Q21 | $1.143 | −$0.324 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted June 2, 2022 |
| 2Q21 | $1.467 | −$0.156 | 25 MG | Cyclophosphamide oral 25 mg | v1, posted March 1, 2022 |
| 1Q21 | $1.623 | – | 25 MG | Cyclophosphamide oral 25 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.